EyePoint Pharmaceuticals : EYPT Investor Presentation August 2022

Forward-Looking Statements

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP- 1901 as a sustained delivery treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU®; the success of current and future license agreements, including our agreements with Ocumension Therapeutics, Equinox Science and Betta Pharmaceuticals; termination or breach of current license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

2 | IN V E S T O R P R E S ENT A T IO N

COMPANY OVERVIEW

Compelling

Pipeline

Leverages

Proven Durasert®

Technology

3 | IN V E S T O R P R E S ENT A T IO N

EYP-1901 is key pipeline program

• Vorolanib, a TKI in bioerodible Durasert
• Positive safety and efficacy data from Phase 1 DAVIO clinical trial
• Phase 2 DAVIO 2 clinical trial in wet AMD dosed in July 2022; non-proliferative diabetic retinopathy (NPDR) PAVIA trial expected to begin in Q3 2022

Durasert® - proven intravitreal (IVT) drug delivery

• Sustained ocular drug delivery
• Constant (zero-order kinetics) stable release of drug
• Safely administered to over 80,000 patient eyes across four FDA approved products

Strong balance sheet with growing revenue

• $171 million in cash and investments on June 30, 2022
• Cash runway into 2H 2024
• Commercial franchise positioned for 2022 break-even

TECHNOLOGY

DURASERT®

Safe Sustained Intravitreal Drug Delivery

• Used in four of sixFDA approved intravitreal sustained delivery products
• Delivered by a single in-office intravitreal injection
• Continuous, stable release of drug

4 | IN V E S T O R P R E S ENT A T IO N

Non-Erodible Products

• YUTIQ® (EyePoint)
• ILUVIEN® (Alimera)
• RETISERT® (B&L)
• VITRASERT® (B&L)

Bioerodible: EYP-1901

• Polyimide coating eliminated
• Initial drug burst from insert surface
• Constant, zero-order kinetic release over months

EYP-1901: Vorolanib in Bioerodible Durasert®

EYP-1901

• Single IVT injection of up to 3 inserts

• Bioerodible formulation of Durasert

• Initial drug burst from surface of insert to rapidly

		reach therapeutic levels in ocular tissues
		• Zero order kinetics release
		Vorolanib
		• Receptor-binding tyrosine kinase inhibitor (TKI)
		• Binds receptors of all VEGF growth factors
EYP-1901 insert at month 5 post-injection	• Oral formulation studied in Phase 1 and Phase 2 wet
		AMD clinical trials1,2

1. Jackson et al. JAMA Ophthalmol 2017. 2. Cohen MN et al. Br J Ophthalmol. 2021.

5 | IN V E S T O R P R E S ENT A T IO N